Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients

AIDS

Volumn 14, Issue 18, 2000, Pages 2869-2876

  Zhou, Xiao Jian ^a   Havlir, Diane V ^b   Richman, Douglas D ^b   Acosta, Edward P ^a   Hirsch, Martin ^c   Collier, Ann C ^d   Tebas, Pablo ^e   Sommadossi, Jean Pierre ^a,f  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e WASHINGTON UNIVERSITY   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Cerebrospinal fluid penetration; Combination antiretroviral therapy; Indinavir; Population pharmacokinetics

Indexed keywords

INDINAVIR; LAMIVUDINE; ZIDOVUDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PENETRATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS INHIBITION;

ADULT; ANTI-HIV AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; LAMIVUDINE; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; ZIDOVUDINE;

EID: 0034518276     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200012220-00008     Document Type: Article

References (29)

1. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
2. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
3. A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy
4. Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy
5. Rapid quantification of indinavir in human plasma by high-performance liquid chromatography with ultraviolet detection
6. The importance of modeling interoccasion variability in population pharmacokinetic analyses
7. Pharmacokinetics of multiple dosing
8. Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infeced patients
9. Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy
10. Indinavir - A review of its use in the management of HIV infection
11. A 24-week open-label phase I/II evalualion of the HIV protease inhibitor MK-639 (indinavir)
12. Indinavir concentrations and antiviral effect
13. Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1
14. Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor
15. Sex-dependent pharmacokinetics of indinavir: In vivo and in vitro evidence
16. Effect of age and gender on the activity of human hepatic CYP3A
17. Aging and drug interaction. II. Effect of phenytoin and smoking on the oxidation of theophytline and cortisol in healthy men
18. Studies on the expression and metabolic capabilities of human liver cytochrome P-450IIIA5 (HLp3)
19. Pharmacokinetic aspects of drug therapy in the elderly
20. HIV-1, the brain and combination therapy
21. In vivo selection of HIV-1 variants with reduced susceptibility to the protease inhibitor L-735,524 and related compounds
22. L-735,524: An orally bioavailable human immunodeficiency virus type 1 protease inhibitor
23. HIV-1 RNA is not detectable in the cerebrospinal fluid during antiretroviral combination therapy
24. Indinavir-based treatment of HIV-1 infected patients: Efficacy in the central nervous system
25. Therapeutic concentrations of indinavir in cerebrospinal fluid of HIV-1infected patients
26. Antiretroviral drugs and the central nervous system
27. Indinavir in cerebrospinal fluid of HIV-1-infected patients